Companies › Roivant Sciences Ltd.

Roivant Sciences Ltd. (ROIV): Financial Statements and Key Figures

Roivant Sciences Ltd. (ticker ROIV) is classified by the SEC under industry code 2834, Pharmaceutical Preparations, and is listed on Nasdaq. It files its annual report with the U.S. Securities and Exchange Commission (SEC) on Form 10-K and reports in US dollars. Its fiscal 2026 ended on 31 March 2026; the annual report for that year was filed on 20 May 2026. For that year it reported revenue of US$ 8 million, a net loss of US$ 300 million and total assets of US$ 5,709 million at the year end. Fiscal years 2021 to 2026 are shown below.

The figures are as the company filed them, standardised by reporting tag; the filing is the authority. For education and analysis, not investment advice.

Key Figures

Money in US$ millions; earnings per share in US dollars. Free cash flow is the cash from operating activities less capital expenditures. Total debt is short-term plus long-term debt, or the total the company itself tags when that is larger. A margin is the profit line divided by revenue; return on equity is net income divided by the average of shareholders' equity at the start and the end of the year. A blank cell means the company does not report the line under a standard tag; it does not mean zero.

Table 1: Key figures of Roivant Sciences Ltd. by fiscal year
Fiscal year	2021	2022	2023	2024	2025	2026	Last 12 months to 30 Sep 2026
year ended on	31 Mar	31 Mar	31 Mar	31 Mar	31 Mar	31 Mar	not a fiscal year
Revenue (US$ millions)	24	55	32	33	29	8	^‡
Net income (US$ millions)	−809	−845	−1,009	4,349	−172	−300	^‡
Earnings per share, diluted (US$)	−1.28	−1.26	−1.42	5.23	−0.24	−0.54	^‡
Cash from operating activities (US$ millions)	−552	−678	−843	−765	−839	−750	^‡
Free cash flow (US$ millions)	−558	−695	−856	−767	−844	−759	^‡
Total assets (US$ millions)	2,590	2,585	2,390	7,222	5,437	5,709	4,976
Total debt (US$ millions)	170	210	376	431
Shareholders' equity (US$ millions)	1,798	1,657	1,158	5,969	4,688	4,527	4,020
Gross margin							^‡
Operating margin	−4,500.5 %	−2,444.8 %	−2,875.9 %	13,746.9 %	−3,453.3 %	−6,235.7 %	^‡
Net margin	−3,400.9 %	−1,528.9 %	−3,200.2 %	13,294.2 %	−592.0 %	−3,629.2 %	^‡
Return on equity	−45.0 %	−48.9 %	−71.7 %	122.1 %	−3.2 %	−6.5 %

The last column is not a fiscal year. It is the last twelve months to 30 September 2026: the last fiscal year, plus the year to date in the latest quarterly report (Form 10-Q, filed 9 November 2026), less the same year-to-date period a year before; total assets, total debt and equity are those of the quarterly balance sheet. Quarterly reports are unaudited interim data. The column enters no growth rate and no chart.

^‡ Withheld: the tagged figure exists but is known to be incomplete or failed a stated check, so it is not shown (last twelve months: withheld: the twelve-month revenue is 4.97 times the last fiscal year (outside 0.5 to 2), so the year-to-date periods may not match the fiscal year).

Charts

Figure 1: Revenue and net income by fiscal year (US$ millions)

Figure 2: Cash from operating activities and free cash flow by fiscal year (US$ millions)

Compound Growth

The compound annual growth rate is the single yearly rate that, applied every year, takes the first value to the last one: the last value divided by the first, raised to the power of one over the number of years, less one. It uses only the two end values, so an unusual first or last year moves it a great deal.

Revenue: 24 in fiscal 2021 to 8 in fiscal 2026 (US$ millions), 5 years: −19.1 % a year.
Diluted earnings per share: not shown. The rate needs positive diluted earnings per share in the latest fiscal year and in an earlier comparable one.

Analyse This Company

Each link opens a calculator with Roivant Sciences Ltd. loaded from the same data.

Company Financial Statements: The full income statement, balance sheet and cash flow statement of each fiscal year, with common-size and growth views.
Capital Allocation History: Where the cash from operations went each year: capital expenditures, dividends, share repurchases, debt.
Dividend Sustainability: How the dividends paid compare with earnings and with free cash flow, year by year.
Earnings Quality Trend: How much of reported earnings arrived as cash, and how accruals moved over the years.
Reverse DCF: The growth in free cash flow that a share price you type would assume.
Financial Quality Scores: The Piotroski F-score and the DuPont breakdown of return on equity, worked step by step.
Valuation Range: What a share price you type corresponds to as multiples of earnings, cash flow and book value, against the company's own history.

Several companies at once: Peer Comparison and Fundamental Screener.

Same Industry

The first 12 in alphabetical order of the 24 other companies in the data with the industry code 2834 (Pharmaceutical Preparations), in alphabetical order; the index lists every company.

Source

The annual report first filed for each fiscal year, with a link to its index page on EDGAR, the SEC's filing system. A later annual report repeats earlier years for comparison and sometimes restates them; where a value was taken from a later report, the last column gives the date of the latest one used.

Table 2: The filing behind each fiscal year
Fiscal year	Year ended	Form	Filed	On EDGAR	Later report used, filed
2026	31 Mar 2026	Form 10-K	20 May 2026	filing index
2025	31 Mar 2025	Form 10-K	29 May 2025	filing index	20 May 2026
2024	31 Mar 2024	Form 10-K	30 May 2024	filing index	20 May 2026
2023	31 Mar 2023	Form 10-K	28 Jun 2023	filing index	29 May 2025
2022	31 Mar 2022	Form 10-K	28 Jun 2022	filing index	28 Jun 2023
2021	31 Mar 2021	Form 10-K	28 Jun 2022	filing index

The figures are as filed with the SEC and standardised by reporting tag. The filing is the authority: check it before relying on a number.
A blank cell means the company does not tag that line, or the tagged figure is withheld as incomplete. It does not mean zero.
Currency: every figure is in the currency the company reported that year (US dollars here). Nothing is converted.
Per-share figures are adjusted for stock splits detected from the company's own restated figures, except where a year is flagged; the as-filed values are in the filings.
For a bank, broker, insurer or other financial company (SIC codes 6000 to 6799) net debt, EBITDA, the current ratio and debt to equity are not meaningful and the tools show them as n/m.
A fiscal year is named after the calendar year in which it ends. The data is updated from time to time, not daily; this company's figures were loaded on 13 November 2026.

For education and analysis, not investment advice.